Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medical composition for losing weight or treating metabolic syndromes

A technology for metabolic syndrome and composition, applied in the directions of drug combination, metabolic disease, pharmaceutical formulation, etc., can solve the problems of enhancing insulin resistance, no report of orlistat, no report of the synergistic effect of the two drugs, etc., to achieve enhanced diabetes. The effect of good blood pressure, systolic blood pressure and pulse pressure difference, and systolic blood pressure and pulse pressure difference reduction effect

Active Publication Date: 2011-08-17
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The literature did not report that the combination of orlistat and metformin was used to lower blood lipids and enhance insulin resistance, nor did it report whether the combination of the two drugs had a synergistic effect, but only concluded that the effect of the combined drug was better than that of the placebo group

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical composition for losing weight or treating metabolic syndromes
  • Medical composition for losing weight or treating metabolic syndromes
  • Medical composition for losing weight or treating metabolic syndromes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] prescription

[0012] Orlistat 125g

[0013] Pioglitazone Hydrochloride 5g

[0014] Microcrystalline Cellulose 230g

[0015] 8% hydroxypropyl methylcellulose solution appropriate amount

[0016] Low-substituted hydroxypropyl cellulose 150g

[0017] Magnesium Stearate 4.5g

[0018] Preparation process: Orlistat and pioglitazone hydrochloride pass through a 100-mesh sieve, microcrystalline cellulose and low-substituted hydroxypropyl cellulose pass through a 80-mesh sieve, and weigh the prescribed amount of pioglitazone hydrochloride, orlistat and low-substituted hydroxypropyl cellulose Mix the cellulose and microcrystalline cellulose evenly, add an appropriate amount of 8% hydroxypropyl methylcellulose solution to granulate, dry at 60°C, sieve the granules with 16 meshes, add the prescribed amount of magnesium stearate to the dry granules, mix evenly, press Slice and serve.

Embodiment 2

[0020] Orlistat 60g

[0021] Pioglitazone Hydrochloride 15g

[0022] 90g pregelatinized starch

[0023] Mannitol 70g

[0024] Lactose 40g

[0025] 6% PVP in 95% ethanol solution

[0026] Micronized silica gel 5g

[0027] Preparation process: Pass orlistat, pioglitazone hydrochloride, mannitol, lactose and micronized silica gel in the prescription through a 100-mesh sieve, mix well, add 6% PVP in 95% ethanol solution to granulate in an appropriate amount, dry at 60°C, and dry for 18 Mesh sieve for granulation, then fill the capsules.

Embodiment 3

[0029] Orlistat 60g

[0030] Pioglitazone Hydrochloride 10g

[0031] Croscarmell Starch Sodium 140g

[0032] Microcrystalline Cellulose 85g

[0033] Ethylcellulose 3g

[0034] Vitamin E 7g

[0035] Magnesium Stearate 3g

[0036] Preparation process: The sustained-release tablet can be prepared according to the preparation process of the sustained-release tablet.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medical composition for treating metabolic syndromes, belonging to the field of medicines, and in particular relates to a medical composition containing orlistat or cetilistat and actos, wherein the composition is solid preparations such as compressed tablets, dispersible tablets, sustained release tablets, capsules, granules, and the like. In experiments, the medical composition containing the orlistat or the cetilistat and the actos is accidentally found to have obvious synergistic effect on the aspects of reducing the blood pressure, the serum total cholesterol, the serum triglyceride and the low density lipoprotein cholesterin and enhancing the carbohydrate tolerance.

Description

technical field [0001] The invention relates to a pharmaceutical composition for weight loss or treatment of metabolic syndrome, which belongs to the field of medicine. Background technique [0002] Overweight or obesity, accompanied by a series of diseases such as hypertension, hyperlipidemia, hyperglycemia, atherosclerosis and hyperinsulinemia, this phenomenon is called metabolic syndrome in medicine. Metabolic syndrome is a common physical problem faced by the urban population. It can not only increase the risk of diabetes and cardiovascular and cerebrovascular diseases, but also increase the mortality of cardiovascular and cerebrovascular diseases. Metabolic syndrome is a polygenic, inherited disorder that is influenced by the environment. Its clinical feature is the combination of obesity, dyslipidemia, hyperglycemia and hypertension. And these four kinds of diseases are often "collusion", which is the "death quartet" of modern urban people. Therefore, experts appeal...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/536A61K31/4439A61K31/365A61P3/04A61P3/10A61P9/12
Inventor 赵志全程国良
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com